Business Wire

UN Global Climate Senior Advisor Added to Bermuda Climate Summit Lineup

Share

Suzanne Johnson, Senior Advisor, United Nations (UN) Global Compact Ocean Stewardship Coalition, is the latest addition to the impressive list of speakers at the second annual Bermuda Climate Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with KBRA.

Bermuda’s Deputy Premier, The Hon. Walter Roban, JP, MP, will open the Summit on June 26 with a conversation with Jim Nadler, President & CEO, KBRA. Another luncheon keynote will be given by Joshua Rosenberg, Chief Risk Officer, Federal Reserve Bank of New York on June 27.

Suzanne Johnson said, “It will be a pleasure to discuss the UN Global Compact work to advance a more sustainable ocean economy at the Bermuda Climate Summit. I look forward to discussing how ocean industry and finance can help to address the climate and nature crisis with financial service executives, academics and international regulators in attendance at the summit.”

David Hart, CEO, BDA said, “We are honoured to have a leading expert like Suzanne Johnson giving a keynote at our Bermuda Climate Summit joining an already impressive line-up. It is sure to be an incredible two days of informative and collaborative discussions not just about climate related challenges, but how Bermuda is the perfect place to create and deliver innovative solutions to the global marketplace.”

We are strongly encouraging prospective delegates from overseas to secure their room and receive special rates at our event hotel, the Hamilton Princess & Beach Club, by booking online prior to May 25. Click here to register – this year’s theme is: ‘Bermuda - Climate Central’.

Stay tuned to the BDA website for agenda updates– sessions confirmed to date include: Impact of a Changing Climate on Atlantic Hurricane Frequency and Severity moderated by Marla Pourrabbani, Data Scientist, Senior Manager, ESG and Sustainability, Deloitte, with panellists: Dr. Pete Dailey, Head of Research, Aeolus, Liz Henderson, Co-Head Catastrophe Analytics, Executive Managing Director, Reinsurance Solutions, Aon, Dr. Peter Sousounis, Vice President/Director Climate Change Research, Verisk, and Craig Tillman, President, RenaissanceRe Risk Sciences.

How Do You Measure Environmental Impact? will be moderated by Barclay Palmer, Executive Editor and Head of Strategy, Climate and Capital Media, and include panellists, Kevin Cei, Climate and Weather Solutions Executive, Jupiter Intelligence, Michele DeMers, CEO, Boundless Impact Research & Analytics, and Keith Pitts, SVP, Sustainability and Regulatory Strategy, Bioceres Crop Solutions.

What’s Ahead in the United States? will be moderated by John Huff, President & CEO, Association of Bermuda Insurers and Reinsurers (ABIR) and include panellists, Ricardo Lara, Insurance Commissioner, California Department of Insurance, Co-Chair of the NAIC Climate and Resiliency Task Force and Lori Wing-Heier, Director, Alaska Division of Insurance, Co-Chair of the NAIC Climate and Resiliency Task Force.

ESG: Where Does the Road Go From Here? will be moderated by Victoria Harman, Founder and Principal, VL Harmon Advisors, and will include panellists, Prabh Banga, VP Sustainability, Aecon, Harry Masters, Director, Advancing Green, Caroline McGill, Principal, Sustainability, and Impact Investment Strategy, Hillbreak and Patrick Welch, Chief ESG and Ratings Policy Officer, KBRA.

Green Opportunities, an Investor’s Perspective will be moderated by Bill Cox, Global Head of Corporate, Financial and Government Ratings, KBRA, with panellists Alexandra Cooley, Chief Investment Officer, Nuveen, Andrea Griffin, Global Head of Responsible Investments Specialists, HSBC Asset Management and Steve Hatfield, US Head of ESG, Carlyle Group.

Global Climate Risk will be moderated by Jeane Nikolai, Director of Energy, Government of Bermuda, and will include panellists Dr. Mark Guishard, Chartered Meteorologist, Adjunct Scientist and Trustee, BIOS, Dr. Raveem Ismail, Head of Parametric Underwriting, Africa Specialty Risks (ASR Re) and Dr. Simon Young, Senior Director, Willis Towers Watson.

Biodiversity: Our Strongest Natural Defense Against Climate Change will be moderated by Slav Gatchev, Managing Director, Sustainable Debt, The Nature Conservancy, with panellists, Osho Jha, CEO & Co-Founder at dClimate, Co-Founder & Chief Data Scientist at Arbol Inc, James Kench, Head of Insurance, KITA, and Natalia Moudrak, Climate Resiliency Leader, AON.

Climate and the Evolving Regulatory and Reporting Landscape will be moderated by Suzanne Williams-Charles, Director of Policy and Regulation, Corporate Secretary and Data Privacy Officer, ABIR, and feature panellists Ralf Kuerzdoerfer, Deputy Director, Supervision (Insurance), Bermuda Monetary Authority, Sohini Chowdhury, Senior Director, Moody’s Analytics, Ricardo Lara, Insurance Commissioner, California Department of Insurance and Arnaud van Dijk, Partner, ESG, KPMG.

The U.S. Federal Flood Programme and the (Re)Insurance Sector, will be moderated by Peter Giacone, Global Head of Insurance, KBRA and include panelists, Chris Brown – Partner, Mindset, Chlora Lindley-Myers, NAIC President and Director of the Missouri Department of Commerce and Insurance, and Andy Neal, Managing Director, Public Private Partnerships, Aon.

Net Zero? will be moderated by Miqdaad Versi, Head of ESG, Oxbow Partners, UK, and feature panelists Rachael Dalheise. Head of Sustainability, Convex, Andrew MacFarlane, Head of Climate, AXA XL, a Division of AXA, Andrew Smith, Chief Risk and Sustainability Officer, Conduit Re and Dr. Steve Smith- Head of Research & Development, Vantage.

The Power of Partnerships, which will be moderated by Jeff Manson, SVP Underwriting and Head of Global Public Sector Partnership, Renaissance Re Ltd, and will include panellists, Ekhosuehi Iyahen, Secretary General, Insurance Development Forum, Sid Miller, Director, Climate Wise, Rebekah Clement, Head of Sustainability, Lloyds, and Chair of SMI Climate Action Committee, and Tim Nielander, Founder and President, GP3 Institute.

Deep Ocean Solutions will be moderated by William Curry, President and CEO, BIOS, and feature panelists Neil Eckert, Executive Chairman, Conduit Re, Irene Polnyi- Additional Ventures Affiliate, and Mallory Ringham, PhD Chemical Oceanography, Ebb Carbon.

The BDA is grateful for the continued support of our headline sponsor KBRA, as well as: diamond sponsor Conduit Re; platinum sponsor Aon; gold sponsors Deloitte, Fidelis and Hub Culture; and silver sponsors Aeolus, Aspen, AXA XL, Belco, and KPMG. Our supporting sponsors are Butterfield and HSBC. Our media partners are The Insurer, Insurance Insider and Bermuda:Re+ILS. Our spirits partner is Goslings. Other sponsorship opportunities are still available; please e-mail bermudaclimate@bda.bm if you wish to participate.

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Stuart Roberts, Director of Marketing & Communications
stuart@bda.bm | +1 441 707 0038

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye